{
  "abstract": "Introduction\n\nCell expansion is one of the most critical steps in the development of CAR-T cell manufacturing processes because it directly influences cell yield and process performance. The systematic optimization of expansion parameters using primary human T cells is often limited by inter-donor variability, cost, and experimental complexity. So, it is necessary to study more homogeneous populations that allow to stablish standardized conditions in a controlled environment that were able to be used as standard. So, in this study, we developed a Jurkat CAR-CD19 cell-based platform as a reproducible model for optimizing the cell expansion bioprocess under controlled culture conditions.Methods\n\nCAR-CD19-expressing Jurkat cells were pre-generated, molecularly characterized and subsequently used to evaluate key bioprocess variables, including glucose concentration, inoculum density, culture medium composition (RPMI + 10% FBS versus Nutri-T without serum), shaking speed, and different culture operating modes (batch, fed-batch, and semi-perfusion). Cell growth kinetics, metabolite consumption, metabolite production, and CAR expression were evaluated throughout the optimization process.Results\n\nAn intermediate glucose concentration supported cell expansion without additional benefit from higher glucose supplementation. Serum-free Nutri-T medium promoted higher viable cell densities than RPMI (used as control media) under the evaluated conditions. Among the operating modes evaluated, semi-perfusion achieved the highest viable cell density, maintaining high cell viability and a homogeneous CAR-positive cell population at the end of culture in Nutri-T media.Conclusion\n\nThese findings demonstrate that the Jurkat CAR-CD19 model provides a robust and reproducible experimental platform for optimizing cell expansion bioprocesses. While further validation in primary human CAR-T cells is required, this model allows for the systematic evaluation of culture variables, minimizing experimental variability and facilitating early-stage process development for adoptive cell therapies.",
  "abstract_shown": true,
  "affiliations": [
    "Pharmaceutical Biotechnology Laboratory, Faculty of Pharmacy, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.",
    "Secretaría de Ciencia, Humanidades, Tecnología e Innovación, SECIHTI, Mexico City, Mexico.",
    "Comisión Coordinadora de Institutos Nacionales de Salud y Hospitales de Alta Especialidad (CCINSHAE), Ministry of Health (Secretaría de Salud), Mexico City, Mexico.",
    "Immunodeficiencies Research Laboratory and Clinical Immunology Department, Instituto Nacional de Pediatría, Mexico City, Mexico.",
    "Department of Research and Development, Triovance SAPI de CV, Mexico City, Mexico.",
    "Hematopoietic Stem Cell Transplantation and Cell Therapy Program, Instituto Nacional de Pediatría, Mexico City, Mexico."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Hugo E Fuentes-Bustos"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Alejandrina Hernández-López"
    },
    {
      "affs": [
        2
      ],
      "name": "Marta Zapata-Tarrés"
    },
    {
      "affs": [
        3
      ],
      "name": "Juan Carlos Bustamante-Ogando"
    },
    {
      "affs": [
        4
      ],
      "name": "Blanca Angélica Segura-Pacheco"
    },
    {
      "affs": [
        5
      ],
      "name": "Alberto Olaya-Vargas"
    },
    {
      "affs": [
        0
      ],
      "name": "Angélica Meneses-Acosta"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/ay8gyrdn6h3fk.bib",
  "cited_by": 0,
  "doi": "10.3389/fbioe.2026.1917849",
  "fulltext_url": "https://europepmc.org/articles/PMC13683766",
  "id": "ay8gyrdn6h3fk",
  "issns": [
    "2296-4185"
  ],
  "landing_url": "https://europepmc.org/article/MED/42909135",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|CAR-T cell therapy research"
    ]
  ],
  "openalex": "W7220857297",
  "pdf_url": "https://europepmc.org/articles/PMC13683766?pdf=render",
  "pmcid": "PMC13683766",
  "pmid": "42909135",
  "published": "2026-10-07",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/ay8gyrdn6h3fk.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:10Z",
      "native_id": "MED:42909135",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42909135"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|CAR-T cell therapy research",
      "subfield": "oncology"
    }
  ],
  "title": "A CAR/CD19 Jurkat cell model for bioprocess screening and expansion: potential use for CAR-T cells production.",
  "title_text": "A CAR/CD19 Jurkat cell model for bioprocess screening and expansion: potential use for CAR-T cells production.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:10Z",
  "url": "https://research.draconitic.com/paper/ay8gyrdn6h3fk",
  "venue": "Frontiers in bioengineering and biotechnology",
  "versions": []
}